Phase i trial of metronomic oral vinorelbine in patients with advanced cancer

Lakshmi Rajdev, Abdissa Negassa, Qun Dai, Gary Goldberg, Kathy Miller, Joseph A. Sparano

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Antitubulin agents exhibit antiangiogenic effects in vitro and in vivo. We evaluated the safety and feasibility of administering a metronomic schedule of oral vinorelbine designed to optimize its antiangiogenic effects. Methods: Patient with advanced cancer who had progressive disease after standard therapy received oral vinorelbine 3 times weekly (i.e., Monday, Wednesday, Friday) at the 6 dose levels ranging from 20 mg (1 week on, 1 week off) to 50 mg (3 weeks on, 1 week off) in cohorts of 3-6 patients at each dose level using a standard phase I design. Dose-limiting toxicity (DLT) during cycle 1 included: (1) neutrophil nadir < 500/μL attributed to therapy, (2) platelet nadir < 50,000/μL attributed to therapy, (3) grade 3-4 non-hematologic toxicity attributed to therapy, and (4) neutropenia associated with grade 2 fever (i.e., febrile neutropenia). Results: Nineteen patients received 50 cycles of therapy (range 1-11 cycles) at 6 dose levels. There were no dose-limiting toxic events. There were no consistent changes in serum TIE-2 or VCAM-1 levels, or urinary VEGF. One patient with renal cell carcinoma had stable disease for 9 months, and another patient with metastatic prostate cancer had a 70% decline in serum prostate-specific antigen, which lasted 4 months. Conclusions: Oral vinorelbine may be given using a metronomic schedule, 50 mg thrice weekly for three of 4 weeks, with minimal toxicity in patients with advanced cancer.

Original languageEnglish
Pages (from-to)1119-1124
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume68
Issue number5
DOIs
StatePublished - Nov 2011

Fingerprint

Toxicity
Neoplasms
Angiogenesis Inhibitors
Vascular Cell Adhesion Molecule-1
Poisons
Prostate-Specific Antigen
Platelets
Vascular Endothelial Growth Factor A
Appointments and Schedules
Cells
Therapeutics
Febrile Neutropenia
Neutropenia
Serum
Renal Cell Carcinoma
vinorelbine
Prostatic Neoplasms
Neutrophils
Fever
Blood Platelets

Keywords

  • Advanced cancer
  • Metronomic
  • Oral
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Phase i trial of metronomic oral vinorelbine in patients with advanced cancer. / Rajdev, Lakshmi; Negassa, Abdissa; Dai, Qun; Goldberg, Gary; Miller, Kathy; Sparano, Joseph A.

In: Cancer Chemotherapy and Pharmacology, Vol. 68, No. 5, 11.2011, p. 1119-1124.

Research output: Contribution to journalArticle

Rajdev, Lakshmi ; Negassa, Abdissa ; Dai, Qun ; Goldberg, Gary ; Miller, Kathy ; Sparano, Joseph A. / Phase i trial of metronomic oral vinorelbine in patients with advanced cancer. In: Cancer Chemotherapy and Pharmacology. 2011 ; Vol. 68, No. 5. pp. 1119-1124.
@article{62040a77764b4c0e9514fbb55da961c4,
title = "Phase i trial of metronomic oral vinorelbine in patients with advanced cancer",
abstract = "Background: Antitubulin agents exhibit antiangiogenic effects in vitro and in vivo. We evaluated the safety and feasibility of administering a metronomic schedule of oral vinorelbine designed to optimize its antiangiogenic effects. Methods: Patient with advanced cancer who had progressive disease after standard therapy received oral vinorelbine 3 times weekly (i.e., Monday, Wednesday, Friday) at the 6 dose levels ranging from 20 mg (1 week on, 1 week off) to 50 mg (3 weeks on, 1 week off) in cohorts of 3-6 patients at each dose level using a standard phase I design. Dose-limiting toxicity (DLT) during cycle 1 included: (1) neutrophil nadir < 500/μL attributed to therapy, (2) platelet nadir < 50,000/μL attributed to therapy, (3) grade 3-4 non-hematologic toxicity attributed to therapy, and (4) neutropenia associated with grade 2 fever (i.e., febrile neutropenia). Results: Nineteen patients received 50 cycles of therapy (range 1-11 cycles) at 6 dose levels. There were no dose-limiting toxic events. There were no consistent changes in serum TIE-2 or VCAM-1 levels, or urinary VEGF. One patient with renal cell carcinoma had stable disease for 9 months, and another patient with metastatic prostate cancer had a 70{\%} decline in serum prostate-specific antigen, which lasted 4 months. Conclusions: Oral vinorelbine may be given using a metronomic schedule, 50 mg thrice weekly for three of 4 weeks, with minimal toxicity in patients with advanced cancer.",
keywords = "Advanced cancer, Metronomic, Oral, Vinorelbine",
author = "Lakshmi Rajdev and Abdissa Negassa and Qun Dai and Gary Goldberg and Kathy Miller and Sparano, {Joseph A.}",
year = "2011",
month = "11",
doi = "10.1007/s00280-011-1580-5",
language = "English",
volume = "68",
pages = "1119--1124",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Phase i trial of metronomic oral vinorelbine in patients with advanced cancer

AU - Rajdev, Lakshmi

AU - Negassa, Abdissa

AU - Dai, Qun

AU - Goldberg, Gary

AU - Miller, Kathy

AU - Sparano, Joseph A.

PY - 2011/11

Y1 - 2011/11

N2 - Background: Antitubulin agents exhibit antiangiogenic effects in vitro and in vivo. We evaluated the safety and feasibility of administering a metronomic schedule of oral vinorelbine designed to optimize its antiangiogenic effects. Methods: Patient with advanced cancer who had progressive disease after standard therapy received oral vinorelbine 3 times weekly (i.e., Monday, Wednesday, Friday) at the 6 dose levels ranging from 20 mg (1 week on, 1 week off) to 50 mg (3 weeks on, 1 week off) in cohorts of 3-6 patients at each dose level using a standard phase I design. Dose-limiting toxicity (DLT) during cycle 1 included: (1) neutrophil nadir < 500/μL attributed to therapy, (2) platelet nadir < 50,000/μL attributed to therapy, (3) grade 3-4 non-hematologic toxicity attributed to therapy, and (4) neutropenia associated with grade 2 fever (i.e., febrile neutropenia). Results: Nineteen patients received 50 cycles of therapy (range 1-11 cycles) at 6 dose levels. There were no dose-limiting toxic events. There were no consistent changes in serum TIE-2 or VCAM-1 levels, or urinary VEGF. One patient with renal cell carcinoma had stable disease for 9 months, and another patient with metastatic prostate cancer had a 70% decline in serum prostate-specific antigen, which lasted 4 months. Conclusions: Oral vinorelbine may be given using a metronomic schedule, 50 mg thrice weekly for three of 4 weeks, with minimal toxicity in patients with advanced cancer.

AB - Background: Antitubulin agents exhibit antiangiogenic effects in vitro and in vivo. We evaluated the safety and feasibility of administering a metronomic schedule of oral vinorelbine designed to optimize its antiangiogenic effects. Methods: Patient with advanced cancer who had progressive disease after standard therapy received oral vinorelbine 3 times weekly (i.e., Monday, Wednesday, Friday) at the 6 dose levels ranging from 20 mg (1 week on, 1 week off) to 50 mg (3 weeks on, 1 week off) in cohorts of 3-6 patients at each dose level using a standard phase I design. Dose-limiting toxicity (DLT) during cycle 1 included: (1) neutrophil nadir < 500/μL attributed to therapy, (2) platelet nadir < 50,000/μL attributed to therapy, (3) grade 3-4 non-hematologic toxicity attributed to therapy, and (4) neutropenia associated with grade 2 fever (i.e., febrile neutropenia). Results: Nineteen patients received 50 cycles of therapy (range 1-11 cycles) at 6 dose levels. There were no dose-limiting toxic events. There were no consistent changes in serum TIE-2 or VCAM-1 levels, or urinary VEGF. One patient with renal cell carcinoma had stable disease for 9 months, and another patient with metastatic prostate cancer had a 70% decline in serum prostate-specific antigen, which lasted 4 months. Conclusions: Oral vinorelbine may be given using a metronomic schedule, 50 mg thrice weekly for three of 4 weeks, with minimal toxicity in patients with advanced cancer.

KW - Advanced cancer

KW - Metronomic

KW - Oral

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=82455171934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82455171934&partnerID=8YFLogxK

U2 - 10.1007/s00280-011-1580-5

DO - 10.1007/s00280-011-1580-5

M3 - Article

VL - 68

SP - 1119

EP - 1124

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -